600750 Jiangzhong Pharmaceutical
- 27.91
- +0.28+1.01%
Jiangzhong Pharmaceutical News
Jiangzhong Pharmaceutical (600750): Under short-term pressure from a high revenue base, profit growth in the main business exceeded expectations
Core view In 2014, the company achieved revenue of 1,227 billion yuan, a year-on-year decrease of 8.74% (after adjustment); achieved net profit of 267 million yuan, a year-on-year increase of 9.99% (adjusted); achieved net profit without deduction to mother
Jiangzhong Pharmaceutical (600750): Profit growth under the 2024Q1 high base, “improving quality, efficiency, and valuing return” actions are imminent
Incident: 1) On April 26, 2024, the company released its 2024 quarterly report. 2024Q1 achieved revenue of 1,227 billion yuan (yoy -8.74%) and net profit of 267 million yuan (y)
Jiangzhong Pharmaceutical (600750): Under high base, 24Q1 performance is under pressure in the short term, OTC business is growing steadily
Incident: Jiangzhong Pharmaceutical released its 2024 quarterly report. 2024Q1 achieved revenue of 1,227 billion yuan, a year-on-year decrease of 8.74%, and realized net profit of 267 million yuan to mother, an increase of 9.99% over the previous year. Reviews: 2
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit of 267 million yuan in the first quarter increased 9.99% year-on-year
Gelonghui, April 29丨China Resources Pharmaceutical (03320.HK) announced that Jiangzhong Pharmaceutical (600750.SH) achieved operating income of 1,227 billion yuan in the first quarter of 2024, down 8.74% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) was 267 million yuan, up 9.99% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) after deducting non-recurring profit and loss was 264 million yuan, up 16.64% year on year.
Jiangzhong Pharmaceutical (600750.SH) reported first-quarter results with net profit of 267 million yuan, up 9.99% year on year
According to the Zhitong Finance App, Jiangzhong Pharmaceutical (600750.SH) released its report for the first quarter of 2024, achieving revenue of 1,227 billion yuan, a year-on-year decrease of 8.74%. Net profit attributable to shareholders of listed companies was 267 million yuan, an increase of 9.99% over the previous year. Achieved net profit of 264 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 16.64% over the previous year.
Jiangzhong Pharmaceutical (600750): Gastrointestinal category leader's “high dividend+state-owned enterprise” value reshaping
Recommended logic: 1) Build a moat for gastrointestinal categories. It is estimated that in 2024, the scale of the pharmaceutical industry for gastrointestinal diseases in China is expected to reach 63.32 billion yuan, and the penetration rate of the core product, digestive tablets, will further increase. 2) Implementation of equity incentives. Achievements
Jiangzhong Pharmaceutical (600750): Improving Quality and Efficiency, High Growth, Brand Building Results Remarkable
Incident The company released an annual report. In 2023, it achieved revenue of 4.39 billion yuan, +13.00% year on year; realized net profit of 708 million yuan, +18.40% year-on-year, after deducting net profit of 704 million yuan.
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit in 2023 increased by 708 million yuan year on year, up 18.4% year on year
Gelonghui, March 25, 丨 China Resources Pharmaceutical (03320.HK) issued an announcement. Jiangzhong Pharmaceutical (600750.SH) announced its 2023 annual report, with operating revenue of RMB 4.39 billion, up 13.00% year on year; net profit attributable to Jiangzhong Pharmaceutical shareholders of RMB 708 million, up 18.4% year on year; net profit attributable to shareholders of Jiangzhong Pharmaceutical (after deducting non-recurring income or loss) of 704 million yuan, an increase of 38.97% year on year; basic earnings per share were 1.12 yuan. A cash dividend of 7 yuan is distributed for every 10 shares.
Jiangzhong Pharmaceutical (600750): Performance is in line with expectations, high dividends, high quality assets
Event: On March 22, 2024, the company released its 2023 annual report. In 2023, the company achieved operating income of 4.390 billion yuan, an increase of 13.00% over the previous year, and achieved net profit of 708 million yuan to mother
Express News | Jiangzhong Pharmaceutical: Net profit due to mother in 2023 was 708 million yuan, up 18.40% year on year
Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Has Had A Decent Run On The Stock Market: Are Fundamentals In The Driver's Seat?
Jiang Zhong PharmaceuticalLtd's (SHSE:600750) stock is up by 6.7% over the past three months. We wonder if and what role the company's financials play in that price change as a company's long-term f
Express News | Societe Generale Securities: Resumes tracking Jiangzhong Pharmaceutical Co., Ltd. and outperforms the market in ratings.
Jiangzhong Pharmaceutical (600750): Steady performance growth, “high dividend+state-owned enterprise” investment value highlighted
Incident: On January 30, 2024, the company released the main operating data for 2023. According to the company's preliminary accounting, revenue in 2023 increased by about 13% year on year, and net profit to mother increased by about 18% year on year. Steady increase in performance
Jiangzhong Pharmaceutical (600750.SH): Proposes to introduce a restricted stock incentive plan of no more than 7.635 million shares
On January 2, Gelonghui Pharmaceutical (600750.SH) announced the second restricted stock incentive plan. It plans to grant no more than 7.635 million restricted shares to incentive recipients, accounting for 1.21% of the company's total share capital when the draft incentive plan was announced. The first incentive was awarded to no more than 213 people, and the award price was 12.79 yuan/share.
Jiangzhong Pharmaceutical (600750.SH): The main sales channel for lumkinase enteric capsules is in primary medical institutions such as level-II hospitals, clinics, health hospitals, etc.
Gelonghui, December 28, 丨 Jiangzhong Pharmaceutical (600750.SH) said on the investor interactive platform that the main sales channels for vermickinase enteric capsules are in primary medical institutions such as level-II hospitals, clinics, health hospitals, etc., and are currently not a type included in national collection. The data disclosed by the company in the regular report “Winning Bids for Major Drugs in Centralized Drug Bidding and Procurement During the Reporting Period” is mainly the online bid winning situation in some provinces, so there is a certain difference from the disclosed data on production volume and sales volume.
Jiangzhong Pharmaceutical (600750.SH): Changes in the shareholding structure of the controlling shareholder
Glonghui December 26丨Jiangzhong Pharmaceutical (600750.SH) announced that China Resources Pharmaceutical Holdings, Jiangxi Guokong, and Xinhai Runda, the corporate shareholders of China Resources Jiangzhong have signed a “Share Transfer Agreement”; Xinhai Runda transferred 14.4412% of China Resources Jiangzhong's shares to China Resources Pharmaceutical Holdings and Jiangxi State Control's original relative shareholding ratio in China Resources Jiangzhong, of which 9.2138% of China Resources Jiangzhong's shares held by China Resources Pharmaceutical Holdings was transferred to China Resources Pharmaceutical Holdings, and 5.2274% of China Resources Jiangzhong's holdings were transferred to Jiangxi State Control Equity. In accordance with the above equity transfer matters, China Resources Jiangzhong has already announced on 2023/12
Jiangzhong Pharmaceutical (600750.SH): Stomach Health and Digestion Tablets Lift Payment Restrictions in the 2023 National Health Insurance Catalogue
<国家基本医疗保险、工伤保险和生育保险药品目录 (2023年) >Gelonghui on December 14丨Jiangzhong Pharmaceutical (600750.SH) announced that on December 13, 2023, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the “Notice on Issuance” (Health Insurance Development [2023] No. 30) (known as the “2023 National Health Insurance Catalogue”). The company's main product, stomach health and digestion tablets, has been adjusted in the “2023 National Health Insurance Catalogue” and the “children only” payment scope has been lifted.
Is Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Jiang Zhong PharmaceuticalLtd (SHSE:600750) has had a great run on the share market with its stock up by a significant 10% over the last three months. Given that stock prices are usually aligned wit
Jiangzhong Pharmaceutical: Purchased 100% of Jiangzhong Changrun's shares and 100% of Jiangzhong Materia Medica's shares for 13.476,900 yuan
Gelonghui November 24 | Jiangzhong Pharmaceutical announced that it will purchase 100% of the shares of Jiangxi Jiangzhong Changrun Pharmaceutical Co., Ltd. held by Jiangxi Jiangzhong Traditional Chinese Medicine Investment and Development Co., Ltd. and 100% of the shares of Jiangxi Jiangzhong Materia Medica Health Technology Co., Ltd. for 13.476,900 yuan.
Jiangzhong Pharmaceutical (600750.SH) distributed 0.6 yuan per share for the first three quarters. The registration date is November 24
Jiangzhong Pharmaceutical (600750.SH) announced that the company will implement equity distribution for the first three quarters of 2023, with each share...
Analysis
Price Target
No Data
